Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Uncategorized Posts

    Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells

    May 2nd, 2024

    Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells

    Jian Song1, Xiaobo Wang2, Jiaxue Zhu3, Jun Liu4 1Department of Orthopaedics, Shandong Jining No.1 People’s Hospital, Jining, Shandong, 272000, China;…

    Read Article

    Dan Hurley, M.D. Endowment Fund

    April 24th, 2024

    Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his…

    Read Article

    Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes


    Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,…

    Read Article

    Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes


    Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,…

    Read Article

    Chondrosarcoma Foundation Efforts to Promote Genomic Sequencing Tests

    April 22nd, 2024

    Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…

    Read Article

    Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options

    April 4th, 2024

    Abstract
    This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal…

    Read Article

    Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

    March 26th, 2024

    Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report Veronika Blum, 1 , † Vanghelita Andrei, 2 , † Baptiste Ameline, 2 Silvia Hofer, 3 Bruno Fuchs, 1 Klaus Strobel, 1 Anna Allemann, 1 Beata Bode, 4…

    Read Article

    Chondrosarcoma Foundation Introduces a new Patient Guide: Making the Decision to enroll in a Clinical Trial.

    March 3rd, 2024

    Typically after surgery, it is important to know what post-surgical options are available. Making the decision to enroll in a clinical trial is one of those options and maybe one of the most important decisions chondrosarcoma patients and their…

    Read Article

    Chondrosarcoma Foundation Efforts to Promote Genomic Sequencing

    February 25th, 2024

    Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…

    Read Article

    Dan Hurley, M.D. Endowment Fund for Insurance Authorizations

    February 23rd, 2024

    Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his…

    Read Article